EnsoData’s Actuarial Analysis of Untreated OSA Reveals the Expansive Impact OSA has on Chronic Comorbid Conditions and Healthcare CostsThe importance of sleep health is no revelation to the field of sleep medicine. Outside of sleep medicine, however, it often goes under the radar. At EnsoData, our hope is to provide sleep professionals with resources to elevate the awareness and importance of sleep health and its effect on healthcare costs and chronic comorbid conditions within health organizations. That’s why we conducted the OSA actuarial study presented in our latest research webinar: The Impact of OSA Therapy on Healthcare Costs. As alluded to in the title, in this EnsoData webinar, EnsoData CEO and Co-Founder, Chris Fernandez, presented insights and takeaways from recent research examining the economic impact of Obstructive Sleep Apnea (OSA) therapy compliance. He covers EnsoData’s motivations behind the research, the collaborators who helped make this research project possible, and the study sample itself, which included over 2 million Medicare patients nationwide. However, the real meat of the presentation comes in the data analysis, including the important relationship between sleep apnea and total medical spend, and more specifically how treated sleep apnea reduces total medical spend by ~20%. To conclude his presentation, Chris outlined the co-prevalence of chronic, high-cost comorbidities and sleep apnea, the impact this research may have, and future work that EnsoData has planned. And you can’t miss the panel-style Q&A session with study collaborators:
- Ian Duncan, PhD, FSA, MAAA, Adjunct Professor of Actuarial Statistics, University of California Santa Barbara, President, Santa Barbara Actuaries Inc.
- Nathaniel F. Watson, MD, MSc, Adjunct Professor, Department of Neurological Surgery, University of Washington (UW) School of Medicine, Principal, NeuroSleep LLC
- Jen McClurg, MBA, SVP Payor Solutions, EnsoData